We are pleased to share a new publication from COST Action ENOTTA (CA21147) entitled: “From reactive to predictive: Advancing biologic dosing in dermatology”
Biologic therapies have transformed the management of chronic inflammatory dermatoses such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. However, standardised dosing regimens often fail to account for inter-individual variability, leading to suboptimal exposure, loss of response, or adverse effects in clinical practice.
In this review, the authors:
-
Highlight key limitations of current biologic dosing strategies in dermatology
-
Examine the role of therapeutic drug monitoring (TDM) in dose optimisation
-
Explore model-informed precision dosing (MIPD) as a forward-looking, data-driven approach integrating pharmacokinetic–pharmacodynamic modelling, Bayesian forecasting, and patient-specific factors
-
Discuss how digital health tools and point-of-care testing can enable predictive, personalised dosing in clinical settings
The work positions MIPD as a paradigm shift, moving biologic therapy from reactive adjustments toward proactive, patient-centred dosing with the potential to improve outcomes, reduce toxicity, and enhance long-term treatment sustainability in dermatology.
This publication reflects ENOTTA’s commitment to advancing precision medicine through interdisciplinary research and innovation.
You can access the publication here : From reactive to predictive: Advancing biologic dosing in dermatology – PubMed
